

Meet our companies at booth 2109 - France pavilion — cc

DISCOVER 7 STARTUPS HERE, AND MANY MORE IN OUR TERRITORY AND THE EUROBIOMED BIOCLUSTER

],]

AMYLGEN



CEO: Vanessa VILLARD

Founded: 2009 Staff: 12

Keywords: Alzheimer's Disease / Neuroprotection / Brain / Ageing / Memory / Anxiety / Depression / Psychosis / ALS / HD

AMYLGEN is a privately-owned CRO offering unique integrated services combining validated *in vivo* models with a full range of behavioral, biochemical and morphological analyses allowing fast and predictive screening of drugs and nutraceuticals on brain health. Our rodent models allow the testing of products on a variety of neurological and, more particularly, neurodegenerative diseases such as Alzheimer's disease, as well as on brain ageing.

amylgen.com • vanessa.villard@amylgen.com • @Amylgen

BIODOL THERAPEUTICS



CEO: Fabien GRANIER

Founded: 2015

Staff: 7

Keywords: Neuropathic pain / Inflammatory pain / Nociceptive pain / Morphine dose sparing

BIODOL Therapeutics develops first-in-class compounds for pain, including the first-ever specific treatment of neuropathic pain (NP). Part of the novel treatments are based on the discovery, published in Nature Communications in 2018, of the critical role of FLT3 in NP. Moreover, recent parallel discoveries by BIODOL Therapeutics extend the scope of pain indications targeted by the company to those treated with opioids, which may help fight the "Opioid Crisis".

biodol.eu • fabien.granier@biodol.eu

CILCARE



CEO: Celia BELLINE **Founded:** 2014

Staff: 20

Keywords: Ear disorders / Hearing / Otology / Tinnitus / Otitis / Preclinical services / CRO / Pharmacology / PK/PD / Toxicology / Otic diseases

CILcare is recognized as the world's leading CRO dedicated to ear disorders. Based in France and in Boston, MA, CILcare supports pharma, medtech, nutraceutical, and veterinary industries to assess efficacy and safety of compounds on hearing loss, tinnitus, and otic disorders. Our services include pharmacokinetics, preclinical efficacy studies, GLP ototoxicity studies, and consulting from target identification to the set up of human clinical trial protocols.

cilcare.com • celia.belline@cilcare.com • @cilcare

CILOA



CEO: Robert MAMOUN

Founded: 2011

Staff: 8

Keywords: Exosome / Therapeutic vector / Therapeutic antibody / Vaccine / GPCR / Kinase receptor / transporter / Oncology / Neuronal disease / Infectious disease / Heart disease / BBB

Ciloa is an experienced exosome-based R&D powerhouse dedicated to developing innovative preventive and therapeutic solutions. Its disruptive in vivo technology customizes exosomes with any membrane and/or cytosolic protein to create (i) virus-free exosome-based therapeutic vectors with the potential to deliver specifically chosen cargos to any diseased organ; (ii) therapeutic antibodies against challenging targets (GPCRs, kinase receptors, ion channels, transporters, viral envelope proteins...); and (iii) virus- and adjuvant-free vaccines against emerging viruses.

ciloa.fr • mkong@ciloa.fr • @ciloabiotech



CEO: Emmanuel PETIOT

Founded: 2006 Staff: 62

Keywords: Microorganisms / Biotechnology / Healthcare / Antibiotics / Antioxidants / Cosmetics / Feed

DEINOVE is a French biotech company that discovers and develops innovative compounds for the healthcare, nutrition, and cosmetics markets. The company leverages broad biodiversity and an integrated platform encompassing screening, genetic engineering, bioinformatics, fermentation, etc. The healthcare business is focused on the discovery, optimization, and development of new antimicrobials, and is run by a number of recognized experts in anti-infectives. Our portfolio includes a clinical-stage antibiotic molecule, and cosmetic active ingredients already on the market.

deinove.com • sebastien.enault@deinove.com • @Deinove

MEDINCELL

CEO: Christophe DOUAT

Founded: 2002 Staff: 130

Keywords: Long-acting injectables / Purposeful innovation

MedinCell is a pharmaceutical company that develops a portfolio of long-acting injectable products in various therapeutic areas by combining its proprietary BEPO® technology with active ingredients already known and marketed. Through the controlled and extended release of the active pharmaceutical ingredient, MedinCell makes medical treatments more efficient, particularly thanks to improved compliance, i.e. compliance with medical prescriptions, and to a significant reduction in the quantity of medication required as part of a one-off or chronic treatment. BEPO® technology makes it possible to control and guarantee the regular delivery of a drug at the optimal therapeutic dose for several days, weeks, or months starting from the subcutaneous or local injection of a simple deposit of a few millimeters, fully bioresorbable. Based in Montpellier, MedinCell currently employs more than 130 people representing of over 25 different nationalities.

medincell.com communication@medincell.com@MedinCell

OXELTIS



CEO: Dr. Jean-Marc ALLAIRE

Founded: 2010 Staff: 19

Keywords: Services in medicinal chemistry and custom synthesis

OXELTIS is a medicinal chemistry services company. The company has a small-scale custom synthesis business, as well as hit and lead optimization services, mainly in the areas of antivirals, antibiotics, and anticancer compounds.

The OXELTIS team comprises experienced medicinal chemists with expertise in particular areas of organic synthesis: heterocycles, modified sugars and oligo/polysaccharides, nucleos(t)ides, macrocycles. The team focuses on speed, quality and confidentiality in the services and collaborative ventures that it develops with its clients in Europe and North America.

oxeltis.com • allaire.jean-marc@oxeltis.com

EUROBIOMED BIOCLUSTER



ViedinCell

EUROBIOMED is the catalyst of the health sector in Southern France. EUROBIOMED leads territorial initiatives, provides resources and offers solutions for businesses and research organizations. EUROBIOMED helps them innovate, finance, develop, and achieve their strategic and business objectives to ultimately improve life through innovations in health. Founded in 2005 by regional stakeholders, EUROBIOMED tops European rankings in all stages of innovation: education, basic research, translational and clinical research, technological innovation centers, start-ups and industrial success stories. Together, the + 390 EUROBIOMED members from about 330 different companies are a driving force in regional development (with 284 projects, representing 1,066 billion Euros).

▶ eurobiomed.org/en/ • contact@eurobiomed.org • @eurobiomed

MONTPELLIER MÉDITERRANÉE MÉTROPOLE

50 place Zeus - CS 39556 34961 Montpellier cedex 2 - France

MONTPELLIER FRANCE HEALTH HUB

Trias ASTÉRIOU - Health Project Manager t.asteriou@montpellier3m.fr








#MontpellierFranceHealthHub

@MTPCapitalSante



May